Skip to Main Content

Anticoagulation for Stroke Prevention and Recovery After ICH (ASPIRE)

Conditions

Diseases of the Cardiovascular System | Diseases of the Nervous System

Phase III

What is the purpose of this trial?

Brief Summary:

Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF).

Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.

  • Ages
    18 years and older
  • Gender
    Both
Find out more about who can participate in this trial
  • Trial with
    University of Cincinnati
  • Start Date
    06/19/2020
  • End Date
    04/30/2024

For more information about this study, contact:

Sara Jasak

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Sub-Investigators

  • Last Updated
    11/15/2021
  • Study HIC
    #2000026409

Contact Information

For more information about this study, including how to volunteer, contact Sara Jasak

Volunteer Now